Evidence map›Paper›PMID 39204342›Full record

ArticlePharmaceutics2024

In Silico Screening Identification of Fatty Acids and Fatty Acid Derivatives with Antiseizure Activity: In Vitro and In Vivo Validation.

Emilia Mercedes Barrionuevo, Estefanía Peralta, Agustín Manzur De Nardi, Juliana Monat, Maximiliano José Fallico, Manuel Augusto Llanos, Luciana Gavernet, Emilio Román Mustafá, Pedro Martin, Alan Talevi

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emilia Mercedes BarrionuevoLaboratory of Bioactive Compound Research and Development (LIDeB), Faculty of Exact Sciences, National University of La Plata (UNLP), Blvd. 120 1489, La Plata 1900, Argentina.
Estefanía PeraltaLaboratory of Bioactive Compound Research and Development (LIDeB), Faculty of Exact Sciences, National University of La Plata (UNLP), Blvd. 120 1489, La Plata 1900, Argentina.
Agustín Manzur De NardiInstituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), Universidad Nacional de La Plata-CICPBA-CONICET, Boulevard 120 no. 1489, La Plata 1900, Argentina.ORCID 0009-0002-4968-1962
Juliana MonatInstituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), Universidad Nacional de La Plata-CICPBA-CONICET, Boulevard 120 no. 1489, La Plata 1900, Argentina.ORCID 0009-0006-0607-6681
Maximiliano José FallicoLaboratory of Bioactive Compound Research and Development (LIDeB), Faculty of Exact Sciences, National University of La Plata (UNLP), Blvd. 120 1489, La Plata 1900, Argentina.
Manuel Augusto LlanosLaboratory of Bioactive Compound Research and Development (LIDeB), Faculty of Exact Sciences, National University of La Plata (UNLP), Blvd. 120 1489, La Plata 1900, Argentina.
Luciana GavernetLaboratory of Bioactive Compound Research and Development (LIDeB), Faculty of Exact Sciences, National University of La Plata (UNLP), Blvd. 120 1489, La Plata 1900, Argentina.ORCID 0000-0001-9285-3788
Emilio Román MustafáElectrophysiology Laboratory of the Multidisciplinary Institute of Cell Biology [Argentine Research Council (CONICET), Scientific Research Commission of the Province of Buenos Aires (CIC-PBA) and National University of La Plata (UNLP)], La Plata 1900, Argentina.
Pedro MartinInstituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), Universidad Nacional de La Plata-CICPBA-CONICET, Boulevard 120 no. 1489, La Plata 1900, Argentina.
Alan TaleviLaboratory of Bioactive Compound Research and Development (LIDeB), Faculty of Exact Sciences, National University of La Plata (UNLP), Blvd. 120 1489, La Plata 1900, Argentina.

Funding

Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación PICT 2019-0406Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación PICT 2019-1075Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación PICT 2021-0300
6 · The paper itself

Abstract

High fat diets have been used as complementary treatments for seizure disorders for more than a century. Moreover, many fatty acids and derivatives, including the broad-spectrum antiseizure medication valproic acid, have been explored and used as pharmacological agents to treat epilepsy. In this work, we have explored the anticonvulsant potential of a large library of fatty acids and fatty acid derivatives, the LIPID MAPS Structure Database, using structure-based virtual screening to assess their ability to block the voltage-gated sodium channel 1.2 (NaV1.2), a validated target for antiseizure medications. Four of the resulting in silico hits were submitted for experimental confirmation using in vitro patch clamp experiments, and their protective role was evaluated in an acute mice seizure model, the Maximal Electroshock seizure model. These four compounds were found to protect mice against seizures. Two of them exhibited blocking effects on NaV1.2, CaV2.2, and CaV3.1.

Indexed as

CaV2.2CaV3.1epilepsyfatty acidsfree fatty acidsketogenic dietmolecular dockingmolecular dynamicsNaV1.2nutraceuticals

Identifiers

PMID39204342
PMCPMC11357650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.